Strongbridge Biopharma PLC (NASDAQ:SBBP) was upgraded by Zacks Investment Research from a “sell” rating to a “hold” rating in a note issued to investors on Wednesday. The firm currently has a $7.25 price target on the biotechnology company’s stock. Zacks Investment Research‘s price objective suggests a potential upside of 15.08% from the company’s current price.
According to Zacks, “Strongbridge Biopharma PLC is a biopharmaceutical company which develops, acquires and commercializes product candidates that target rare diseases. Its product candidate consists of COR-003, is a cortisol inhibitor, for the treatment of endogenous Cushing’s syndrome, COR-004 and COR-005 to treat acromegaly, BP-2001, the treatment of diabetes which are in different clinical trial. Strongbridge Biopharma PLC is based in Trevose, Pennsylvania. “
SBBP has been the subject of several other research reports. ValuEngine cut Strongbridge Biopharma PLC from a “hold” rating to a “sell” rating in a report on Monday, October 2nd. Oppenheimer Holdings, Inc. started coverage on Strongbridge Biopharma PLC in a report on Thursday, August 10th. They issued an “outperform” rating and a $12.00 price target for the company. One research analyst has rated the stock with a sell rating, one has given a hold rating and three have given a buy rating to the stock. Strongbridge Biopharma PLC currently has a consensus rating of “Hold” and a consensus price target of $11.81.
Shares of Strongbridge Biopharma PLC (SBBP) traded down 0.79% during midday trading on Wednesday, hitting $6.25. 28,644 shares of the company were exchanged. Strongbridge Biopharma PLC has a 52-week low of $2.00 and a 52-week high of $8.85. The company has a 50-day moving average price of $6.69 and a 200-day moving average price of $5.76. The stock’s market capitalization is $220.84 million.
Strongbridge Biopharma PLC (NASDAQ:SBBP) last posted its quarterly earnings results on Monday, August 7th. The biotechnology company reported ($0.34) EPS for the quarter, meeting the consensus estimate of ($0.34). The business had revenue of $1.53 million during the quarter, compared to analysts’ expectations of $0.84 million. On average, analysts forecast that Strongbridge Biopharma PLC will post ($2.28) EPS for the current year.
WARNING: This report was reported by Markets Daily and is the sole property of of Markets Daily. If you are viewing this report on another domain, it was illegally copied and reposted in violation of US & international trademark & copyright legislation. The legal version of this report can be accessed at https://www.themarketsdaily.com/2017/10/13/zacks-investment-research-upgrades-strongbridge-biopharma-plc-sbbp-to-hold.html.
Institutional investors and hedge funds have recently bought and sold shares of the business. State of Wisconsin Investment Board purchased a new stake in Strongbridge Biopharma PLC in the 2nd quarter valued at about $114,000. Nexthera Capital LP purchased a new stake in Strongbridge Biopharma PLC in the 2nd quarter valued at about $477,000. California State Teachers Retirement System purchased a new stake in Strongbridge Biopharma PLC in the 2nd quarter valued at about $277,000. State Street Corp purchased a new stake in Strongbridge Biopharma PLC in the 2nd quarter valued at about $443,000. Finally, Rhumbline Advisers purchased a new stake in Strongbridge Biopharma PLC in the 2nd quarter valued at about $154,000. Institutional investors own 62.79% of the company’s stock.
About Strongbridge Biopharma PLC
Strongbridge Biopharma plc is a global commercial-stage biopharmaceutical company. The Company is focused on the development and commercialization of therapies for a range of diseases. The Company’s commercial product, KEVEYIS (dichlorphenamide), is indicated for the treatment of hyperkalemic, hypokalemic and related variants of primary periodic paralysis.
Receive News & Ratings for Strongbridge Biopharma PLC Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Strongbridge Biopharma PLC and related companies with MarketBeat.com's FREE daily email newsletter.